Would azathioprine in inflammatory bowel disease be a risk factor for Strongyloides stercoralis infection?

Authors

  • José Antonio Chehuen Neto Universidade Federal de Juiz de Fora
  • Pedro Duarte Gaburri
  • Aécio Flávio Meireles de Souza
  • Lívia dos Remédios Pamplona de Oliveira
  • Fernanda Santos Silva
  • Luciana de Paula Vianna

Keywords:

Doença de Crohn, Retocolite Ulcerativa, Azatioprina, Estrongiloidíase,

Abstract

Although azathioprine is one of the most common immunomodulatory drugs used in the treatment of Crohn’s disease and ulcerative colitis, some patients can develop imunnosuppression. Strongyloides stercoralis infection may be associated with immunocompromised patients. In this study, our aim was to evaluate the prevalence of this infection in patients with Inflammatory bowel disease being treated with azathioprine, through parasitologic stool examination. The association between peripheral blood eosinophil counts and the infection was also studied. In the group treated with azathioprine, 5.8% (4/69) patients were infected by Strongyloides stercoralis and showed high level of eosinophil. In the other group, treated with different drug, only one patient (1.8%) revealed the infection and the number of eosinophil was normal. These observations demonstrated that the infection caused by this parasite was more frequent in patients from rural area. Besides, the high level of eosinophil could be an indirect marker for this infection.

Downloads

Download data is not yet available.

Published

2007-11-29

How to Cite

1.
Neto JAC, Gaburri PD, Souza AFM de, Oliveira L dos RP de, Silva FS, Vianna L de P. Would azathioprine in inflammatory bowel disease be a risk factor for Strongyloides stercoralis infection?. HU Rev [Internet]. 2007Nov.29 [cited 2024May17];32(2):32-6. Available from: https://periodicos.ufjf.br/index.php/hurevista/article/view/12

Issue

Section

Artigos Originais

Most read articles by the same author(s)

1 2 > >>